XORTX Surges 62% in U.S. Premarket as Peer-Reviewed Research Backs Company's Approach to Polycystic Kidney Disease
XORTX Surges 62% in U.S. Premarket as Peer-Reviewed Research Backs Company's Approach to Polycystic Kidney Disease
XORTX在美国盘前暴涨62%,同行评议的研究支持该公司对多囊肾病的治疗方法
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册